- Jun 21, 2022
National Cancer Institute: Clinical Trials Information for Patients and Caregivers
- Jun 11, 2022
Patient Education: Dexamethasaone (Decadron) and other Steroids
- Jun 10, 2022
Patient Education: Selinexor (Xpovio) - XPO1 inhibitor
- May 31, 2022
Dana-Farber's 2022 Multiple Myeloma Patient Symposium - Update on Multiple Myeloma Treatment
- May 14, 2022
You are central to the care team: Be Empowered - IMF Patient & Family Webinar - May 14, 2022
- May 6, 2022
PE: CDC Guidelines: How to prevent infections (Sepsis) while getting chemotherapy?
- Apr 29, 2022
Patient Education: Bortezomib (Velcade) - Proteasome Inhibitor
- Apr 29, 2022
Patient Education: Carfilzomib (Kyprolis) - Proteasome Inhibitor
- Apr 29, 2022
Patient Education: Ixazomib (Ninlaro) - Proteasome Inhibitor
- Apr 18, 2022
Siteman Cancer Center: Autologous stem cell transplant at Siteman Cancer Center
- Apr 13, 2022
Teva Announces Launch of a First Generic Version of Revlimid® (lenalidomide capsules), in the U.S.
- Apr 12, 2022
How to Prevent Neutropenic Sepsis on Treatment? Know Your ANC (Absolute Neutrophil Count)
- Apr 10, 2022
MPE survey on myeloma and AL amyloidosis diagnosis
- Mar 31, 2022
IMF - International Myeloma Foundation: Patient Handbook 2022
- Mar 30, 2022
Patient Education: Thalidomide (Thalomid) Immunomodulatory Agents - IMIDS
- Mar 30, 2022
Patient Education: Revlimid (lenalidomide) - Immunomodulatory Agents - IMIDS
- Mar 30, 2022
What is Multiple Myeloma? www.uptodate.com
- Mar 30, 2022
Patient Education: Pomalidomide (Pomalyst) Immunomodulatory Agents - IMIDS
- Mar 28, 2022
The Binding Site: Freelite Overview